Clinical trial

Efficacy and Side Effects of 8% Sulphur-Aloe Vera Soap Versus Bland Soap as an Adjuvant of Ketoconazole 2% Shampoo for the Treatment of Pityriasis Versicolor: Open Controlled Trial

Name
DV-202309.02
Description
Pityriasis versicolor (PV) is a superficial, mild, often chronic recurring infection of the skin caused by Malassezia species which is characterized by the formation of hypopigmented, hyperpigmented and/or erythematous macules. It commonly occurs on the trunk and proximal extremities, but can also be found on the entire body. Diagnosis of PV established based on clinical features and microscopic examination with potassium hydroxide. The goals of PV treatment are: to eradicate the hyphae, disappearance of clinical signs and symptoms, to lessen recurrences, and improve patient's quality of life. Topical antifungal remains first line therapy and search for an ideal topical agent of PV continue. Various studies reported combining more than one topical agents can increase the efficacy, thus result in faster mycological cure.
Trial arms
Trial start
2023-08-25
Estimated PCD
2023-12-31
Trial end
2024-01-31
Status
Completed
Phase
Early phase I
Treatment
8% sulphur and A. vera soap
Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
Arms:
8% sulphur and A. vera soap and ketoconazole 2% shampoo, Bland soap and ketoconazole 2% shampoo
Other names:
Blacksoap
Size
42
Primary endpoint
Clinical assessment of pruritus
28 days
Scaling severity
28 days
Mycological cure
28 days
Eligibility criteria
Inclusion Criteria: 1. Male or female 2. Age 18-65 years 3. Diagnosed as PV based on clinical features, microscopic examination using 10% potassium hydroxide, and Wood's lamp Exclusion Criteria: 1. Pregnant or lactating women 2. PV with concurrent skin conditions (dermatitis or skin lesions in form of vesicles or blister or pustules or erosions or excoriation) with body surface area \>30% 3. Use of topical antifungal and/or corticosteroid 14 days prior to study entry 4. Use of systemic antifungal and/or corticosteroid 30 days prior to study entry 5. History of allergy to shampoo or soap containing ketoconazole, sodium lauryl sulphate, sulphur, A. vera, charcoal powder, glycerin, or perfume.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 42, 'type': 'ACTUAL'}}
Updated at
2024-03-26

1 organization

1 product

1 indication